文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤剂量递增试验中光子或质子放疗期间解剖变化对肿瘤剂量的影响

The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials.
PubMed 文献 · Radiother Oncol · 2021-09-28

本研究对24例胶质母细胞瘤患者模拟光子与质子剂量递增计划(75 Gy/30次),比较计划MRI与治疗中MRI上高危亚体积的剂量覆盖变化。中位间隔26天,仅3例(12.5%)出现光子及质子计划剂量覆盖显著恶化,均位于次全切除患者,光子覆盖下降>5%、质子>10%。结论认为解剖变化所致临床相关低剂量仅见于少数患者,不太可能解释剂量递增研究的阴性结果。

要点

  • 24例胶质母细胞瘤患者模拟光子与质子75 Gy/30次剂量递增计划。
  • 仅3例(12.5%)治疗中MRI显示高危亚体积剂量覆盖显著恶化。
  • 剂量覆盖下降>5%(光子)和>10%(质子)者均为次全切除患者。

核心结论

  • 仅少数患者放疗期间解剖变化导致光子或质子计划高危亚体积出现潜在临床相关低剂量。
  • 因此治疗中体积变化不太可能是剂量递增研究阴性结果的原因。

研究设计与样本

  • 对24例胶质母细胞瘤患者基于放疗前计划MRI模拟光子与质子剂量递增计划(75 Gy/30次)。
  • 高危亚体积覆盖切除腔和/或T1增强后MRI上的强化病灶。
  • 另获取治疗中MRI评估该高剂量区剂量分布变化。

主要发现

  • 计划MRI与治疗中MRI中位间隔26天(范围16-37天)。
  • 计划MRI至放疗开始中位时间7天(范围3-11天)。
  • 3例(12.5%)出现光子及质子计划剂量覆盖显著恶化,均为次全切除患者。
  • 上述患者光子计划剂量覆盖下降>5%,质子计划下降>10%。

关键数值与推荐

  • 剂量递增计划总剂量75 Gy/30次。
  • 剂量覆盖下降>5%(光子)和>10%(质子)被视为显著恶化。

临床怎么用

  • 对胶质母细胞瘤剂量递增放疗,治疗中解剖变化所致高危亚体积低剂量仅见于少数患者。
  • 次全切除患者可能需关注治疗中剂量覆盖变化。

局限性

  • 样本量仅24例,观察到的显著变化事件仅3例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Most dose-escalation trials in glioblastoma patients integrate the escalated dose throughout the standard course by targeting a specific subvolume. We hypothesize that anatomical changes during irradiation may affect the dose coverage of this subvolume for both proton- and photon-based radiotherapy. MATERIAL AND METHODS: For 24 glioblastoma patients a photon- and proton-based dose escalation treatment plan (of 75 Gy/30 fr) was simulated on the dedicated radiotherapy planning MRI obtained before treatment. The escalated dose was planned to cover the resection cavity and/or contrast enhancing lesion on the T1w post-gadolinium MRI sequence. To analyze the effect of anatomical changes during treatment, we evaluated on an additional MRI that was obtained during treatment the changes of the dose distribution on this specific high dose region. RESULTS: The median time between the planning MRI and additional MRI was 26 days (range 16-37 days). The median time between the planning MRI and start of radiotherapy was relatively short (7 days, range 3-11 days). In 3 patients (12.5%) changes were observed which resulted in a substantial deterioration of both the photon and proton treatment plans. All these patients underwent a subtotal resection, and a decrease in dose coverage of more than 5% and 10% was observed for the photon- and proton-based treatment plans, respectively. CONCLUSION: Our study showed that only for a limited number of patients anatomical changes during photon or proton based radiotherapy resulted in a potentially clinically relevant underdosage in the subvolume. Therefore, volume changes during treatment are unlikely to be responsible for the negative outcome of dose-escalation studies.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hessen ED, Makocki S, van der Heide UA, et al. The impact of anatomical changes during photon or proton based radiation treatment on tumor dose in glioblastoma dose escalation trials. Radiother Oncol. 2021. PMID: 34592361. doi:10.1016/j.radonc.2021.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。